OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
Shiho Suzuki, Keisuke Suzuki, Tomohiko Shiina, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 17
Shiho Suzuki, Keisuke Suzuki, Tomohiko Shiina, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 17
Showing 17 citing articles:
Switching CGRP(r) MoAbs in migraine: what evidence?
William Wells-Gatnik, Paolo Martelletti
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 5, pp. 327-333
Closed Access | Times Cited: 9
William Wells-Gatnik, Paolo Martelletti
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 5, pp. 327-333
Closed Access | Times Cited: 9
Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers
Mamoru Shibata, Kazuki Fujita, Eri Hoshino, et al.
BMC Neurology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Mamoru Shibata, Kazuki Fujita, Eri Hoshino, et al.
BMC Neurology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence
Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, et al.
Brain Sciences (2024) Vol. 14, Iss. 9, pp. 948-948
Open Access | Times Cited: 4
Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, et al.
Brain Sciences (2024) Vol. 14, Iss. 9, pp. 948-948
Open Access | Times Cited: 4
Efficacy and Safety of Switching Between Anti-CGRP Monoclonal Antibodies: A Detailed Monthly and Long-term Follow-up Study and Literature Review
Kota Oshima, Keiko Ihara, Narumi Watanabe, et al.
Internal Medicine (2025)
Open Access
Kota Oshima, Keiko Ihara, Narumi Watanabe, et al.
Internal Medicine (2025)
Open Access
Switching between anti-cgrp monoclonal antibodies in migraine prophylaxis
Michail Vikelis, Dimitrios Rikos, Andreas A. Argyriou, et al.
Expert Review of Neurotherapeutics (2025)
Closed Access
Michail Vikelis, Dimitrios Rikos, Andreas A. Argyriou, et al.
Expert Review of Neurotherapeutics (2025)
Closed Access
Efficacy and continuability of 675 mg fremanezumab administration over 2 years
Shohei Yoshida, Noboru Imai, Masato Keicho, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Shohei Yoshida, Noboru Imai, Masato Keicho, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data
Carmen Sánchez-Rodríguez, Ana Beatriz Gago‐Veiga, David García‐Azorín, et al.
Current Pain and Headache Reports (2023)
Closed Access | Times Cited: 7
Carmen Sánchez-Rodríguez, Ana Beatriz Gago‐Veiga, David García‐Azorín, et al.
Current Pain and Headache Reports (2023)
Closed Access | Times Cited: 7
Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
Seiya Ohtani, Narumi Watanabe, Keiko Ihara, et al.
BMC Neurology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 7
Seiya Ohtani, Narumi Watanabe, Keiko Ihara, et al.
BMC Neurology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 7
A Review of Calcitonin Gene-Related Peptide and Its Implications for Vestibular Disorders
R L Baron, Kristen K. Steenerson
Current Treatment Options in Neurology (2024) Vol. 26, Iss. 6, pp. 203-228
Closed Access | Times Cited: 2
R L Baron, Kristen K. Steenerson
Current Treatment Options in Neurology (2024) Vol. 26, Iss. 6, pp. 203-228
Closed Access | Times Cited: 2
Cgrp Monoclonal Antibodies: Key Lessons from Real World Evidence
Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, et al.
(2024)
Open Access | Times Cited: 2
Bianca Orlando, Gabriella Egeo, Cinzia Aurilia, et al.
(2024)
Open Access | Times Cited: 2
The history and rationale of the development of new drugs for migraine treatment
Pedro André Kowacs, Pedro Augusto Sampaio Rocha‐Filho, Mário Fernando Prieto Peres, et al.
Arquivos de Neuro-Psiquiatria (2023) Vol. 81, Iss. 12, pp. 1084-1097
Open Access | Times Cited: 6
Pedro André Kowacs, Pedro Augusto Sampaio Rocha‐Filho, Mário Fernando Prieto Peres, et al.
Arquivos de Neuro-Psiquiatria (2023) Vol. 81, Iss. 12, pp. 1084-1097
Open Access | Times Cited: 6
Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study
Laura Zanandrea, Roberta Messina, Ilaria Cetta, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 12
Open Access | Times Cited: 1
Laura Zanandrea, Roberta Messina, Ilaria Cetta, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 12
Open Access | Times Cited: 1
Switching from ligand to receptor anti‐calcitonin gene‐related peptide (CGRP ) antibodies or vice versa in non‐responders: A controlled cohort study
Nancy van Veelen, Britt W. H. van der Arend, E. Hiele, et al.
European Journal of Neurology (2024)
Open Access
Nancy van Veelen, Britt W. H. van der Arend, E. Hiele, et al.
European Journal of Neurology (2024)
Open Access
The Impact of Migraine on the Whole Life Course of Patients: Results from the OVERCOME (Japan) 2nd Study
Daisuke Danno, Shiho Suzuki, Tsubasa Takizawa, et al.
Neurology and Therapy (2024)
Open Access
Daisuke Danno, Shiho Suzuki, Tsubasa Takizawa, et al.
Neurology and Therapy (2024)
Open Access
Modern pharmacotherapeutic strategies in the treatment of migraine: from the signaling pathways of calcitonin gene-related peptide (CGRP) to novel therapeutic agents
Fedir Hladkykh
Psychiatry Neurology and Medical Psychology (2024), Iss. 26, pp. 447-475
Open Access
Fedir Hladkykh
Psychiatry Neurology and Medical Psychology (2024), Iss. 26, pp. 447-475
Open Access
Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule
Shiho Suzuki, Keisuke Suzuki, Tomohiko Shiina, et al.
Journal of the Neurological Sciences (2023) Vol. 455, pp. 122786-122786
Closed Access | Times Cited: 1
Shiho Suzuki, Keisuke Suzuki, Tomohiko Shiina, et al.
Journal of the Neurological Sciences (2023) Vol. 455, pp. 122786-122786
Closed Access | Times Cited: 1
